E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with titanium press-fit acetabular components with polyethylene liners will be screened for osteolytic lesions. The patients had primary surgery at least 7 years before screening and all operated due to osteoarthritis of the hip. We expect that approximately 30% of screened patients will have an osteolytic lesion. These patients with screening-detected lesions as well as patients with previously known osteolytic lesions will be eligible for inclusion in the study. |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with hip implants (THA) performed at least 7 years before inclusion with possible or known loosening of implant due to bone dissolution (osteolytic lesions). |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective is to study the efficacy of denosumab in reducing wear-induced osteolysis around uncemented acetabular implants used in THA. |
|
E.2.2 | Secondary objectives of the trial |
The change in volume of the osteolytic lesion over 2 years.
Percentage change of the lesion over the study period.
Hip-specific outcome scores at inclusion and 1, 2 and 3 years.
Percent change in BMD in vertebrae L1-L4 to investigate if there is an overall increase in bone mass in these patients.
Correlation between change in bone turnover markers and progression of osteolysis.
Changes in Serum Concentrate values for RANKL and Osteoprogesterin, to determine how Serum level correlates with changes in Osteolytic Volume.
Occurrence of AE´s.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Age 40-85 years
• Short Portable Mental Status Questionnaire (SPMSQ) also named Pfeiffertest ≥7 correct responses or alternatively ≤ 3 incorrect responses
• Male and females
• The primary THA performed at least 7 years before inclusion.
• The primary THA performed due to osteoarthritis or congenital dysplasia of the hip.
• Uncemented cup fixation
• Baseline osteolytic lesion of at least 2 cm³ and at most 40 cm³ around an uncemented acetabular component with a polyethylene liner.
• Participant is willing and able to follow study protocol and has provided informed consent prior to any study specific procedures.
|
|
E.4 | Principal exclusion criteria |
• Women that are pregnant or women planning to become pregnant or planning to breastfeed
• For women of childbearing potential (menopausal state -determined??): Subject refuses to use 1 highly effective method of contraception (contraceptive pill, intra uterine contraceptive device) for the duration of the study and for 5 months after the last dose of study medication.
• For women of childbearing potential: Subject refrain from breastfeeding for the duration of the study and for 5 months after the last dose of study medication.
• For males with a partner of childbearing potential: Subject refuses to use a condom for the duration of the study and for 5 months after the last dose of study medication.For males with a partner who is pregnant: Subject refuses to use a condom for the duration of the study and for 5 months after the last dose of study medication.
• Women that are pregnant or breastfeeding or women planning to become pregnant or planning to breastfeed.
• Pain in the operated hip (because the presence of hip pain in combination with an osteolytic lesion is an indication for revision surgery) as defined by a visual analog scale (VAS) score >3
• Previous revision surgery of the hip i.e. exchange of any inplant after the primary surgery
• Inflammatory arthritis
• Previous participation in clinical trials with denosumab or administration of commercial denosumab (Prolia™ or Xgeva™)
• Currently enrolled in or has not yet completed at least 1 month since ending other investigational device or drug trial(s), or subject is receiving other investigational agent(s).
• Treatment with any intravenous bisphosphonate, fluoride (except for dental treatment) or strontium ranelate within 5 years prior to inclusion.
• Treatment with any oral bisphosphonate within 1 year prior to inclusion.
• Treatment with cortisol or cytostatic drugs within 6 months prior to inclusion.
• Administration of any of the following treatments 3 months prior to screening:
Anabolic steroids or testosterone
Glucocorticosteroids (≥ 5 mg prednisone equivalent per day for more than 10 days or a total cumulative dose of ≥ 50 mg)
Calcitonin
Calcitriol or vitamin D derivatives [vitamin D contained in supplements or multivitamins is allowed]
Other bone active drugs including anti-convulsives (except benzodiazepines, gabapentin and pregabalin) and heparin
Chronic systemic ketoconazole, ACTH (adrenocorticotrophic hormone), cinacalcet, aluminum, lithium, protease inhibitors, methotrexate, gonadotropin-releasing hormone agonists.
Androgen deprivation therapy
• Hypocalcaemia.
• Bone metabolic disorders (such as OI, PHPT, Paget)
• History of osteonecrosis of the jaw and/or recent (within prior 6 months) tooth extraction or dental surgery; or planned invasive dental proceedures during the study
• Serum 25-OH D <15 ng/ml
• Significant malabsorption including Celiac Disease, Short Bowel Syndrome, Crohn’s Disease, Previous Gastric Bypass.
• Active cancer and/or malignancy in last 5 years (except cervical carcinoma in situ or basal cell carcinoma)
• History of solid organ or bone marrow transplant.
• Hypersensitivity to any components of study drug.
• Intolerance to calcium supplements.
• Pregnancy and/or currently lactating.
• Significantly impaired renal function as determined by a derived glomerular filtration rate (GFR) using Cockcroft Gault formula of 30 mL/min/1.73 m2
• Elevated transaminases ≥ 2.0 x upper limit of normal (ULN); Elevated total bilirubin (TBL) > 1.5 x ULN.
• Any condition or illness (acute, chronic, or history), which in the opinion of the Investigator might interfere with the evaluation of efficacy and safety during the study or may otherwise compromise the safety of the subject.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The change in volume of the osteolytic lesion over 3 years (measured with 3D-CT in cm³):
Efficacy(3 years) = Volume(3 years) - Volume(baseline). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
The change in volume of the osteolytic lesion over 2 years (measured with 3D-CT in cm³)
Efficacy (2 years) = Volume (2years ) - Volume (baseline).
Percentage change of the lesion over the study period.(14)
Hip-specific outcome scores (Harris hip score(31)[HHS], WOMAC (32)), Pain Numerical Rating Scale (PNRS), Activity Scores (UCLA and Johnston) and Health-related quality of life (EQ-5D)(33) at inclusion and 1, 2 and 3 years.
Percent change from baseline in BMD in vertebrae L1-L4 and measured with dual-energy x-ray absorptiometry (DXA) at 3 years to investigate if there is an overall increase in bone mass in these patients. Previous studies on denosumab have focused on patients with osteoporosis or other metabolic bone disease and it is to be expected that the patients in this trial will have a normal bone mass.
Correlation between change in bone turnover markers 6 months after first injection and progression of osteolysis . Serum C-terminal telopeptide of type I collagen (SCTx)(34) and procollagen type 1 amino-terminal propeptide (P1NP)(35) will be controlled through blood samples at inclusion and every 6 months (before each injection).
Exploratory Endpoints.
Changes in Serum Concentrate values for RANKL and Osteoprogesterin, to determine how Serum level correlates with changes in Osteolytic Volume
Occurrence of AE´s
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Screening/randomization, 6 months, 1 year, 1.5 years, 2 years. 2.5 years and 3 years. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |